

Bronwen E Shaw

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8768604/publications.pdf>

Version: 2024-02-01

187
papers

6,323
citations

66343

42
h-index

82547

72
g-index

193
all docs

193
docs citations

193
times ranked

6609
citing authors

#	ARTICLE	IF	CITATIONS
1	Current Use of and Trends in Hematopoietic Cell Transplantation in the United States. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e177-e182.	2.0	378
2	Effect of T-cell-epitope matching at HLA-DPB1 in recipients of unrelated-donor haemopoietic-cell transplantation: a retrospective study. <i>Lancet Oncology</i> , The, 2012, 13, 366-374.	10.7	289
3	Diagnosis and management of acute graft-versus-host disease. <i>British Journal of Haematology</i> , 2012, 158, 30-45.	2.5	281
4	Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study. <i>Lancet Haematology</i> , the, 2021, 8, e185-e193.	4.6	271
5	EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment. <i>Bone Marrow Transplantation</i> , 2018, 53, 1401-1415.	2.4	243
6	Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation. <i>Blood</i> , 2014, 124, 2596-2606.	1.4	228
7	Selection of unrelated donors and cord blood units for hematopoietic cell transplantation: guidelines from the NMDP/CIBMTR. <i>Blood</i> , 2019, 134, 924-934.	1.4	199
8	The importance of HLA-DPB1 in unrelated donor hematopoietic cell transplantation. <i>Blood</i> , 2007, 110, 4560-4566.	1.4	166
9	Diagnosis and management of chronic graft-versus-host disease. <i>British Journal of Haematology</i> , 2012, 158, 46-61.	2.5	152
10	Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a prospective trial from the National Marrow Donor Program. <i>Blood</i> , 2013, 121, 197-206.	1.4	123
11	Lower risk for serious adverse events and no increased risk for cancer after PBSC vs BM donation. <i>Blood</i> , 2014, 123, 3655-3663.	1.4	112
12	Comparison of Patient-Reported Outcomes in 5-Year Survivors Who Received Bone Marrow vs Peripheral Blood Unrelated Donor Transplantation. <i>JAMA Oncology</i> , 2016, 2, 1583.	7.1	110
13	Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma. <i>British Journal of Haematology</i> , 2005, 129, 631-643.	2.5	109
14	Development of an Unrelated Donor Selection Score Predictive of Survival after HCT: Donor Age Matters Most. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1049-1056.	2.0	98
15	The impact of extramedullary disease at presentation on the outcome of myeloma. <i>Leukemia and Lymphoma</i> , 2009, 50, 230-235.	1.3	97
16	Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor T Cell Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 34-43.	2.0	93
17	National Marrow Donor Program-Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide. <i>Journal of Clinical Oncology</i> , 2021, 39, 1971-1982.	1.6	90
18	HLA-DPB1 matching status has significant implications for recipients of unrelated donor stem cell transplants. <i>Blood</i> , 2006, 107, 1220-1226.	1.4	87

#	ARTICLE	IF	CITATIONS
19	The Microbiome and Hematopoietic Cell Transplantation: Past, Present, and Future. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1322-1340.	2.0	85
20	Recipients Receiving Better HLA-Matched Hematopoietic Cell Transplantation Grafts, Uncovered by a Novel HLA Typing Method, Have Superior Survival: A Retrospective Study. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 443-450.	2.0	84
21	The impact of HLA genotyping on survival following unrelated donor haematopoietic stem cell transplantation. <i>British Journal of Haematology</i> , 2010, 150, 251-258.	2.5	83
22	Recommendations for a standard UK approach to incorporating umbilical cord blood into clinical transplantation practice: an update on cord blood unit selection, donor selection algorithms and conditioning protocols. <i>British Journal of Haematology</i> , 2016, 172, 360-370.	2.5	79
23	Concerns about the use of biosimilar granulocyte colony-stimulating factors for the mobilization of stem cells in normal donors: position of the World Marrow Donor Association. <i>Haematologica</i> , 2011, 96, 942-947.	3.5	75
24	Neurocognitive dysfunction in hematopoietic cell transplant recipients: expert review from the late effects and Quality of Life Working Committee of the CIBMTR and complications and Quality of Life Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2018, 53, 535-555.	2.4	75
25	Organ-specific management and supportive care in chronic graft-versus-host disease. <i>British Journal of Haematology</i> , 2012, 158, 62-78.	2.5	65
26	Cord blood stem cells for hematopoietic stem cell transplantation in the UK: how big should the bank be?. <i>Haematologica</i> , 2009, 94, 536-541.	3.5	63
27	HLA-DP in unrelated hematopoietic cell transplantation revisited: challenges and opportunities. <i>Blood</i> , 2017, 130, 1089-1096.	1.4	60
28	Single Nucleotide Polymorphisms in the <i>NOD2/CARD15</i> Gene Are Associated With an Increased Risk of Relapse and Death for Patients With Acute Leukemia After Hematopoietic Stem-Cell Transplantation With Unrelated Donors. <i>Journal of Clinical Oncology</i> , 2007, 25, 4262-4269.	1.6	58
29	Patient-reported outcomes and health status associated with chronic graft-versus-host disease. <i>Haematologica</i> , 2018, 103, 1535-1541.	3.5	56
30	Metabolic Syndrome and Cardiovascular Disease after Hematopoietic Cell Transplantation: Screening and Preventive Practice Recommendations from the CIBMTR and EBMT. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1493-1503.	2.0	55
31	HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide. <i>Blood</i> , 2022, 139, 1452-1468.	1.4	52
32	Immune-Mediated Complications after Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1368-1375.	2.0	51
33	“Worldwide Network for Blood & Marrow Transplantation (WBMT) special article, challenges facing emerging alternate donor registries”. <i>Bone Marrow Transplantation</i> , 2019, 54, 1179-1188.	2.4	51
34	Real-World Issues and Potential Solutions in Hematopoietic Cell Transplantation during the COVID-19 Pandemic: Perspectives from the Worldwide Network for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research Health Services and International Studies Committee. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2181-2189.	2.0	51
35	Sexual health in hematopoietic stem cell transplant recipients. <i>Cancer</i> , 2015, 121, 4124-4131.	4.1	50
36	Centralized patient-reported outcome data collection in transplantation is feasible and clinically meaningful. <i>Cancer</i> , 2017, 123, 4687-4700.	4.1	50

#	ARTICLE	IF	CITATIONS
37	Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1312-1317.	2.0	49
38	Ocular graft-versus-host disease after hematopoietic cell transplantation: Expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2019, 54, 662-673.	2.4	48
39	A combined DPA1~¼DPB1 amino acid epitope is the primary unit of selection on the HLA-DP heterodimer. <i>Immunogenetics</i> , 2012, 64, 559-569.	2.4	47
40	Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma. <i>Leukemia Research</i> , 2018, 74, 130-136.	0.8	47
41	Hematopoietic Cell Transplantation~“Specific Comorbidity Index Predicts Morbidity and Mortality in Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1646-1650.	2.0	45
42	Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma. <i>British Journal of Haematology</i> , 2008, 141, 235-243.	2.5	44
43	Long~term outcomes among 2~year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large ~cell lymphoma. <i>Cancer</i> , 2018, 124, 816-825.	4.1	44
44	Neurocognitive Dysfunction in Hematopoietic Cell Transplant Recipients: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Complications and Quality of Life Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 228-241.	2.0	43
45	Engraftment of rare, pathogenic donor hematopoietic mutations in unrelated hematopoietic stem cell transplantation. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	41
46	<scp>BCSH</scp>/<scp>BSBMT</scp>/<scp>UK</scp> clinical virology network guideline: diagnosis and management of common respiratory viral infections in patients undergoing treatment for haematological malignancies or stem cell transplantation. <i>British Journal of Haematology</i> , 2016, 173, 380-393.	2.5	40
47	Characteristics of Late Fatal Infections after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 362-368.	2.0	40
48	Survival and Late Effects after Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancy at Less than Three Years of Age. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1327-1334.	2.0	38
49	Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft- <i>versus</i> -host disease: low incidence of lower gastrointestinal tract disease. <i>Haematologica</i> , 2018, 103, 717-727.	3.5	38
50	PROMIS measures can be used to assess symptoms and function in long~term hematopoietic cell transplantation survivors. <i>Cancer</i> , 2018, 124, 841-849.	4.1	38
51	Hematopoietic Cell Transplantation with Cryopreserved Grafts for Severe Aplastic Anemia. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e161-e166.	2.0	38
52	Histologic Features of the Liver Biopsy Predict the Clinical Outcome for Patients with Graft-versus-Host Disease of the Liver. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 805-813.	2.0	37
53	Peripheral Blood Grafts for T Cell~“Replete Haploidentical Transplantation Increase the Incidence and Severity of Cytokine Release Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1664-1670.	2.0	36
54	Determination of Eligibility in Related Pediatric Hematopoietic Cell Donors: Ethical and Clinical Considerations. Recommendations from a Working Group of the Worldwide Network for Blood and Marrow Transplantation Association. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 96-103.	2.0	35

#	ARTICLE	IF	CITATIONS
55	Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remission. <i>Haematologica</i> , 2009, 94, 1399-1406.	3.5	34
56	Late effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemia. <i>Blood Advances</i> , 2020, 4, 983-992.	5.2	34
57	High readmission rates are associated with a significant economic burden and poor outcome in patients with grade <scp>III</scp>/<scp>IV</scp> acute <scp>G</scp>v<scp>HD</scp>. <i>Clinical Transplantation</i> , 2013, 27, E56-63.	1.6	32
58	Health-Related Quality of Life among Pediatric Hematopoietic Stem Cell Donors. <i>Journal of Pediatrics</i> , 2016, 178, 164-170.e1.	1.8	32
59	Remuneration of hematopoietic stem cell donors: principles and perspective of the World Marrow Donor Association. <i>Blood</i> , 2011, 117, 21-25.	1.4	31
60	Outcomes of Measurable Residual Disease in Pediatric Acute Myeloid Leukemia before and after Hematopoietic Stem Cell Transplant: Validation of Difference from Normal Flow Cytometry with Chimerism Studies and Wilms Tumor 1 Gene Expression. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2040-2046.	2.0	29
61	Rates and Risk Factors for Post-Traumatic Stress Disorder Symptomatology among Adult Hematopoietic Cell Transplant Recipients and Their Informal Caregivers. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 145-150.	2.0	28
62	Retrospective cohort analysis comparing the incidence of deep vein thromboses between peripherally-inserted and long-term skin tunneled venous catheters in hemato-oncology patients. <i>Thrombosis Journal</i> , 2015, 13, 21.	2.1	27
63	Race and Ethnicity Influences Collection of Granulocyte Colony-“Stimulating Factor”-Mobilized Peripheral Blood Progenitor Cells from Unrelated Donors, a Center for International Blood and Marrow Transplant Research Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 165-171.	2.0	26
64	The Effect of Donor Graft Cryopreservation on Allogeneic Hematopoietic Cell Transplantation Outcomes: A Center for International Blood and Marrow Transplant Research Analysis. Implications during the COVID-19 Pandemic. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 507-516.	1.2	26
65	Updated Trends in Hematopoietic Cell Transplantation in the United States with an Additional Focus on Adolescent and Young Adult Transplantation Activity and Outcomes. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 409.e1-409.e10.	1.2	26
66	Late cardiovascular morbidity and mortality following pediatric allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 1278-1287.	2.4	25
67	Plerixafor alone for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells. <i>Blood Advances</i> , 2019, 3, 875-883.	5.2	25
68	The Impact of Chimerism Patterns and Predonor Leukocyte Infusion Lymphopenia on Survival following T Cell-Depleted Reduced Intensity Conditioned Transplants. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 550-559.	2.0	24
69	Etanercept and Corticosteroid Therapy for the Treatment of Late-Onset Idiopathic Pneumonia Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1955-1960.	2.0	24
70	Ocular Graft-versus-Host Disease after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e46-e54.	2.0	24
71	In silico prediction of nonpermissive HLA-DPB1 mismatches in unrelated HCT by functional distance. <i>Blood Advances</i> , 2018, 2, 1773-1783.	5.2	23
72	Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Performed in the Inpatient versus Outpatient Setting. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 827-833.	2.0	23

#	ARTICLE	IF	CITATIONS
73	The impact of donor factors on primary non-engraftment in recipients of reduced intensity conditioned transplants from unrelated donors. <i>Haematologica</i> , 2005, 90, 1562-9.	3.5	23
74	Role of Race/Ethnicity in Donor Decisions about Unrelated Hematopoietic Progenitor Cell Donation: Exploring Reasons for Higher Attrition among Racial/Ethnic Minorities. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 593-599.	2.0	22
75	European Group for Blood and Marrow Transplantation Centers with FACT-JACIE Accreditation Have Significantly Better Compliance with Related Donor Care Standards. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 514-519.	2.0	21
76	Female donors and donors who are lighter than their recipient are less likely to meet the <sc>CD</sc>34+ cell dose requested for peripheral blood stem cell transplantation. <i>Transfusion</i> , 2014, 54, 2953-2960.	1.6	20
77	National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Research Methodology and Study Design Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 10-23.	2.0	20
78	Postâ€transplantation employment status of adult survivors of childhood allogeneic hematopoietic cell transplant: A report from the Center for International Blood and Marrow Transplant Research (CIBMTR). <i>Cancer</i> , 2019, 125, 144-152.	4.1	20
79	TGFB1 Functional Polymorphisms: Impact on Outcome in Allogeneic Unrelated Donor Haematopoietic Stem Cell Transplantation. <i>Blood</i> , 2008, 112, 3011-3011.	1.4	20
80	Ifosfamide, etoposide and epirubicin is an effective combined salvage and peripheral blood stem cell mobilisation regimen for transplant-eligible patients with non-Hodgkin lymphoma and Hodgkin disease. <i>British Journal of Haematology</i> , 2007, 136, 752-761.	2.5	19
81	Impact of Previously Unrecognized HLA Mismatches Using Ultrahigh Resolution Typing in Unrelated Donor Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2021, 39, 2397-2409.	1.6	19
82	Unrelated donor peripheral blood stem cell transplants incorporating preâ€transplant <i>inâ€vivo</i> Alemtuzumab are not associated with any increased risk of significant acute or chronic graftâ€versusâ€host disease. <i>British Journal of Haematology</i> , 2011, 153, 244-252.	2.5	18
83	Treosulfan, Fludarabine, and Low-Dose Total Body Irradiation for Children and Young Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation: Prospective Phase II Trial of the Pediatric Blood and Marrow Transplant Consortium. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1651-1656.	2.0	18
84	Related haploidentical donors are a better choice than matched unrelated donors: Counterpoint. <i>Blood Advances</i> , 2017, 1, 401-406.	5.2	17
85	Changes in Hematopoietic Cell Transplantation Practices in Response to COVID-19: A Survey from the Worldwide Network for Blood & Marrow Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 270.e1-270.e6.	1.2	17
86	Harvests from bone marrow donors who weigh less than their recipients are associated with a significantly increased probability of a suboptimal harvest yield. <i>Transfusion</i> , 2016, 56, 1052-1057.	1.6	16
87	Non-Graft-versus-Host Disease Ocular Complications after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 25, 145-154.	2.0	16
88	High Absolute T Regulatory Cell Counts and Resistance of CD8 Central Memory Cells to Killing by Fludarabine Predicts for Poor Responses to DLI in the Context of a Pre-DLI Lymphoreduction Strategy. <i>Blood</i> , 2011, 118, 1912-1912.	1.4	16
89	Current use of biosimilar G-CSF for haematopoietic stem cell mobilisation. <i>Bone Marrow Transplantation</i> , 2019, 54, 858-866.	2.4	15
90	Significant Improvements in the Practice Patterns of Adult Related Donor Care in US Transplantation Centers. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 520-527.	2.0	14

#	ARTICLE	IF	CITATIONS
91	Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. Bone Marrow Transplantation, 2019, 54, 648-661.	2.4	14
92	Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases. Blood Advances, 2020, 4, 2084-2094.	5.2	14
93	Likelihood of Proceeding to Allogeneic Hematopoietic Cell Transplantation in the United States after Search Activation in the National Registry: Impact of Patient Age, Disease, and Search Prognosis. Transplantation and Cellular Therapy, 2021, 27, 184.e1-184.e13.	1.2	14
94	Optimal Donor Selection for Hematopoietic Cell Transplantation Using Bayesian Machine Learning. JCO Clinical Cancer Informatics, 2021, 5, 494-507.	2.1	14
95	The Concentration of Total Nucleated Cells in Harvested Bone Marrow for Transplantation Has Decreased over Time. Biology of Blood and Marrow Transplantation, 2019, 25, 1325-1330.	2.0	13
96	Related peripheral blood stem cell donors experience more severe symptoms and less complete recovery at one year compared to unrelated donors. Haematologica, 2019, 104, 844-854.	3.5	13
97	Predictors of Loss to Follow-Up Among Pediatric and Adult Hematopoietic Cell Transplantation Survivors: A Report from the Center for International Blood and Marrow Transplant Research. Biology of Blood and Marrow Transplantation, 2020, 26, 553-561.	2.0	13
98	Fludarabine/Busulfan Conditioning-Based Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis: Role of Ruxolitinib in Improving Survival Outcomes. Biology of Blood and Marrow Transplantation, 2020, 26, 893-901.	2.0	13
99	Immunogenetic factors in donors and patients that affect the outcome of hematopoietic stem cell transplantation. Blood Cells, Molecules, and Diseases, 2008, 40, 40-43.	1.4	12
100	Analysis of the Effect of Race, Socioeconomic Status, and Center Size on Unrelated National Marrow Donor Program Donor Outcomes: Donor Toxicities Are More Common at Low-Volume Bone Marrow Collection Centers. Biology of Blood and Marrow Transplantation, 2015, 21, 1830-1838.	2.0	12
101	Health-Related Quality of Life among Older Related Hematopoietic Stem Cell Donors (>60 Years) Is Equivalent to That of Younger Related Donors (18 to 60 Years): A Related Donor Safety Study. Biology of Blood and Marrow Transplantation, 2017, 23, 165-171.	2.0	12
102	Graft Versus Host Disease Clinical Trials: Is it Time for Patients Centered Outcomes to Be the Primary Objective?. Current Hematologic Malignancy Reports, 2019, 14, 22-30.	2.3	12
103	Community health status and outcomes after allogeneic hematopoietic cell transplantation in the United States. Cancer, 2021, 127, 609-618.	4.1	12
104	Progressive Arterial Thrombosis in a Patient with Non-Hodgkin's Lymphoma, a Lupus Anticoagulant, Factor V Leiden Mutation and Paraprotein, Following Chemotherapy. Leukemia and Lymphoma, 2001, 42, 221-223.	1.3	11
105	Predonation Health-Related Quality of Life Scores Predict Time to Recovery in Hematopoietic Stem Cell Donors. Biology of Blood and Marrow Transplantation, 2015, 21, 350-356.	2.0	11
106	CD25 Blockade Delays Regulatory T Cell Reconstitution and Does Not Prevent Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2017, 23, 405-411.	2.0	11
107	Effect of Aging and Predonation Comorbidities on the Related Peripheral Blood Stem Cell Donor Experience: Report from the Related Donor Safety Study. Biology of Blood and Marrow Transplantation, 2019, 25, 699-711.	2.0	11
108	Prevalence of decisional regret among patients who underwent allogeneic hematopoietic stem cell transplantation and associations with quality of life and clinical outcomes. Cancer, 2020, 126, 2679-2686.	4.1	11

#	ARTICLE	IF	CITATIONS
109	The frequency of HLA-B*57:01 and the risk of abacavir hypersensitivity reactions in the majority population of Costa Rica. <i>Human Immunology</i> , 2014, 75, 1092-1096.	2.4	10
110	Risk Factors for Subsequent Central Nervous System Tumors in Pediatric Allogeneic Hematopoietic Cell Transplant: A Study from the Center for International Blood and Marrow Transplant Research (CIBMTR). <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1320-1326.	2.0	10
111	Urgent Time to Allogeneic Hematopoietic Cell Transplantation: A National Survey of Transplant Physicians and Unrelated Donor Search Coordinators Facilitated by the Histocompatibility Advisory Group to the National Marrow Donor Program. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2501-2506.	2.0	10
112	Transplant center practices for psychosocial assessment and management of pediatric hematopoietic stem cell donors. <i>Bone Marrow Transplantation</i> , 2019, 54, 1780-1788.	2.4	10
113	Return to Work Among Young Adult Survivors of Allogeneic Hematopoietic Cell Transplantation in the United States. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 679.e1-679.e8.	1.2	10
114	Biobehavioral Research and Hematopoietic Stem Cell Transplantation: Expert Review from the Biobehavioral Research Special Interest Group of the American Society for Transplantation and Cellular Therapy. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 747-757.	1.2	10
115	Prevention of relapse after allogeneic hematopoietic cell transplantation by donor and cell source selection. <i>Bone Marrow Transplantation</i> , 2018, 53, 1498-1507.	2.4	9
116	A Conceptual Framework and Key Research Questions in Educational Needs of Blood and Marrow Transplantation Patients, Caregivers, and Families. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1416-1423.	2.0	9
117	First do no harm. <i>Blood</i> , 2010, 115, 4978-4979.	1.4	8
118	Female Sex is Associated With Poor Health-related Quality of Life in Children at 12 Months Post-Hematopoietic Cell Transplantation. <i>Journal of Pediatric Hematology/Oncology</i> , 2019, 41, 233-237.	0.6	8
119	Presence of donor-encoded centromeric KIR B content increases the risk of infectious mortality in recipients of myeloablative, T-cell deplete, HLA-matched HCT to treat AML. <i>Bone Marrow Transplantation</i> , 2020, 55, 1975-1984.	2.4	8
120	Matching Status at Amino Acid Positions 57 and 65 of the HLA-DPB1 Beta Chain Determines Outcome in Recipients of Unrelated Donor Haematopoietic Stem Cell Transplants.. <i>Blood</i> , 2004, 104, 827-827.	1.4	8
121	Alpha-1 antitrypsin for the treatment of steroid-refractory acute gastrointestinal graft-versus-host disease. <i>American Journal of Hematology</i> , 2017, 92, E610-E611.	4.1	7
122	Use of propylene glycol-free melphalan conditioning in light-chain amyloidosis patients undergoing autologous hematopoietic cell transplantation is well tolerated and effective. <i>Bone Marrow Transplantation</i> , 2018, 53, 1210-1213.	2.4	7
123	Donor Experiences of Second Marrow or Peripheral Blood Stem Cell Collection Mirror the First, but CD34+ Yields Are Less. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 175-184.	2.0	7
124	Higher Risks of Toxicity and Incomplete Recovery in 13- to 17-Year-Old Females after Marrow Donation: RDSafe Peds Results. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 955-964.	2.0	7
125	Risk factors for the development of cutaneous melanoma after allogeneic hematopoietic cell transplantation. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 762-772.	1.2	7
126	Impact of autologous blood transfusion after bone marrow harvest on unrelated donor's health and outcome: a CIBMTR analysis. <i>Bone Marrow Transplantation</i> , 2020, 55, 2121-2131.	2.4	7

#	ARTICLE	IF	CITATIONS
127	Clonal Hematopoiesis in Related Allogeneic Transplant Donors: Implications for Screening and Management. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e142-e144.	2.0	7
128	5 Year Results of BMT CTN 0201: Unrelated Donor Bone Marrow Is Associated with Better Psychological Well-Being and Less Burdensome Chronic Gvhd Symptoms Than Peripheral Blood. <i>Blood</i> , 2015, 126, 270-270.	1.4	7
129	Health-Related Quality-of-Life Comparison of Adult Related and Unrelated HSC Donors: An RDSafe Study. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2365-2371.	2.0	6
130	Predicting Mortality after Autologous Transplant: Development of a Novel Risk Score. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1828-1832.	2.0	6
131	Hematopoietic Cell Transplantation: Practice Predictions for the Year 2023. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 183.e1-183.e7.	1.2	6
132	Worldwide Network for Blood and Marrow Transplantation (WBMT) Recommendations Regarding Essential Medications Required To Establish An Early Stage Hematopoietic Cell Transplantation Program. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 267.e1-267.e5.	1.2	6
133	Converting Mixed Chimerism to Full Donor Chimerism in Recipients of Campath-Containing Reduced Intensity Transplants Reduces the Relapse Risk and Results in Significantly Improved Survival Compared to Those with Persistent Full Donor Chimerism.. <i>Blood</i> , 2005, 106, 2026-2026.	1.4	6
134	Prevalence of self-reported sleep dysfunction before allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 1079-1082.	2.4	5
135	Bridging the Gap in Access to Transplant for Underserved Minority Patients Using Mismatched Unrelated Donors and Post-Transplant Cyclophosphamide: A National Marrow Donor Program/be the Match (NMDP/BTM) Initiative. <i>Blood</i> , 2020, 136, 48-49.	1.4	5
136	A Comparison of Stem Cell Source in Adult and Paediatric Recipients of T-Cell Depleted Myeloablative Transplants for Standard Risk Leukaemia: No Difference in Mortality Using BM or PBSC.. <i>Blood</i> , 2009, 114, 1205-1205.	1.4	5
137	Ixazomib for Chronic Graft-versus-Host Disease Prophylaxis following Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1876-1885.	2.0	4
138	Collection of Peripheral Blood Progenitor Cells in 1 Day Is Associated with Decreased Donor Toxicity Compared to 2 Days in Unrelated Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1210-1217.	2.0	4
139	Orca-T, a Precision Treg-Engineered Donor Product, Prevents Acute Gvhd with Less Immunosuppression in an Early Multicenter Experience with Myeloablative HLA-Matched Transplants. <i>Blood</i> , 2020, 136, 47-48.	1.4	4
140	Adding Centralized Electronic Patient-Reported Outcome Data Collection to an Established International Clinical Outcomes Registry. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 112.e1-112.e9.	1.2	4
141	Cryopreservation of Allogeneic Hematopoietic Cell Grafts Did Not Adversely Affect Early Post-Transplant Survival during the First Six Months of the COVID-19 Pandemic. <i>Blood</i> , 2021, 138, 2846-2846.	1.4	4
142	Sickle Cell Transplantation Evaluation of Long-term and Late Effects Registry (STELLAR) to Compare Long-term Outcomes After Hematopoietic Cell Transplantation to Those in Siblings Without Sickle Cell Disease and in Nontransplanted Individuals With Sickle Cell Disease: Design and Feasibility Study. <i>JMIR Research Protocols</i> , 2022, 11, e36780.	1.0	4
143	Immune reconstitution following umbilical cord blood transplantation: IRES, a study of UK paediatric patients. <i>EJHaem</i> , 2020, 1, 208-218.	1.0	3
144	Permissive HLA-DPB1 Mismatching Compared to a Non-Permissive Mismatching Significantly Improves Overall Survival Following Allogeneic Transplantation In Patients with Both 10/10 and 9/10 Matched Unrelated Donors. <i>Blood</i> , 2010, 116, 227-227.	1.4	3

#	ARTICLE	IF	CITATIONS
145	Incidence and characteristics of engraftment syndrome after autologous hematopoietic cell transplantation in light chain amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2019, 26, 210-215.	3.0	2
146	Shorter Interdonation Interval Contributes to Lower Cell Counts in Subsequent Stem Cell Donations. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 503.e1-503.e8.	1.2	2
147	Serious Adverse Events in Related Donors: A Report from the Related Donor Safe Study. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 352.e1-352.e5.	1.2	2
148	Orca-T Results in High Gvhd-Free and Relapse-Free Survival Following Myeloablative Conditioning for Hematological Malignancies: Results of a Single Center Phase 2 and a Multicenter Phase 1b Study. <i>Blood</i> , 2021, 138, 98-98.	1.4	2
149	Unrelated Cord Blood Transplantation in adults: evolution, experience and long-term outcomes in the <scp>UK</scp> National Health Service : a retrospective analysis on behalf of the British Society of Blood and Marrow Transplantation and Eurocord. <i>British Journal of Haematology</i> , 2016, 172, 478-481.	2.5	1
150	4-Locus high-resolution HLA allele and haplotype frequencies in Costa Ricans from African-Caribbean descent. <i>Human Immunology</i> , 2019, 80, 411-412.	2.4	1
151	A reply to Hurley et al. regarding Recipients Receiving Better HLA-Matched Hematopoietic Cell Transplantation Grafts, Uncovered by a Novel HLA Typing Method, Have Superior Survival: A Retrospective Study. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e270-e271.	2.0	1
152	Importance of Assessing Patient-Reported Outcomes With Salvage Autologous Transplantation in Relapsed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2019, 37, 1598-1600.	1.6	1
153	Letter to the Editor Regarding "Diagnostic Considerations for COVID-19 in Recipients of Allogeneic Hematopoietic Cell Transplantation". <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e241-e242.	2.0	1
154	Single HLA Allele Mismatches Are Well Tolerated in the Recipients of T Cell Depleted Reduced Intensity Conditioned Transplants from Unrelated Donors.. <i>Blood</i> , 2005, 106, 2895-2895.	1.4	1
155	Increased Disease Relapse in HLA-DPB1 Matched Recipients of Unrelated Donor Transplants Is Not Confined to Pairs Matched for the Other Five HLA loci.. <i>Blood</i> , 2004, 104, 829-829.	1.4	1
156	NOD2/CARD15 Genotype and HLA-DPB1 Matching Status Can Be Used To Predict Disease Relapse in Recipients of an Unrelated Donor Haematopoietic Stem Cell Transplant for Acute Leukaemia.. <i>Blood</i> , 2007, 110, 830-830.	1.4	1
157	The Impact of Pre-Apheresis Health Related Quality of Life on Peripheral Blood Progenitor Cell Yield and Donor's Health and Outcome: Secondary Analysis of Rdsafe and BMT CTN 0201. <i>Blood</i> , 2021, 138, 1772-1772.	1.4	1
158	HLA typing-A case-based approach to donor selection. <i>Advances in Cell and Gene Therapy</i> , 2018, 1, e16.	0.9	0
159	4-Locus high-resolution HLA allele and haplotype frequencies in admixed population from Nicaragua. <i>Human Immunology</i> , 2019, 80, 417-418.	2.4	0
160	5-Locus high-resolution HLA allele and haplotype frequencies in Costa Ricans from the Central Valley. <i>Human Immunology</i> , 2019, 80, 413-414.	2.4	0
161	4-Locus high-resolution HLA allele and haplotype frequencies in Costa Ricans from Guanacaste. <i>Human Immunology</i> , 2019, 80, 415-416.	2.4	0
162	4-Locus high-resolution HLA allele and haplotype frequencies in Amerindians from Costa Rica. <i>Human Immunology</i> , 2019, 80, 409-410.	2.4	0

#	ARTICLE	IF	CITATIONS
163	Patient and Donor Selection and Workup for Hematopoietic Cell Transplantation. , 2019, , 85-97.		0
164	Primary graft failure, but not relapse, may be identified by early chimerism following double cord unit transplantation. Blood Advances, 2021, , .	5.2	0
165	Pathologic Features May Predict the Clinical Outcome of Hepatic Graft Versus Host Disease (H-GVHD).. Blood, 2004, 104, 5079-5079.	1.4	0
166	Low Pre-DLI Lymphocytes Counts Are Predictive of Good Disease Responses in Patients with Mixed Chimerism Following Campath-Containing Reduced Intensity Transplants.. Blood, 2006, 108, 261-261.	1.4	0
167	Ifosphamide, Etoposide and Epirubicin (IVE) Is an Effective Combined Salvage and Peripheral Blood Stem Cell Mobilisation Regimen for Transplant-Eligible Patients with Lymphoma.. Blood, 2006, 108, 2432-2432.	1.4	0
168	Single Nucleotide Polymorphisms of the NOD2/CARD15 Gene Are Associated with Significant Increases in Disease Relapse and Mortality in Recipients of an Unrelated Donor Haematopoietic Stem Cell Transplant for Acute Leukaemia.. Blood, 2006, 108, 498-498.	1.4	0
169	High Proportions of CD4+CD25hi T Cells Pretransplant Correlate with Worse Overall Survival after Stem Cell Transplant.. Blood, 2006, 108, 3126-3126.	1.4	0
170	Duration of Initial Admission and Subsequent Readmission in the First 100 Days Following Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation.. Blood, 2007, 110, 1999-1999.	1.4	0
171	An Early CT-Diagnosis Based Treatment Strategy for Invasive Fungal Infection in Allogeneic Transplant Recipients Using Caspofungin First Line: An Effective Strategy with Low Mortality.. Blood, 2008, 112, 1149-1149.	1.4	0
172	Autologous Transplantation Is the Optimum Approach to the Management of Myeloma Patients with Extramedullary Disease at Presentation. Blood, 2008, 112, 3313-3313.	1.4	0
173	T-Cell Depleted Unrelated Donor Stem Cell Transplants Appear to Be of Value for Adult Philadelphia Chromosome Negative ALL Patients and Should Be Evaluated Prospectively in New Large Group Studies. Blood, 2008, 112, 4413-4413.	1.4	0
174	A Single Institution's Experience with Allogeneic Haematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukaemia: Analysis of Factors Leading to Improved Outcome. Blood, 2008, 112, 4322-4322.	1.4	0
175	The Presence of Minimal Residual Disease Pre- and Post-Transplant Is Predictive of Outcome in Recipients of Allogeneic Transplantation for Acute Myeloid Leukaemia.. Blood, 2009, 114, 2601-2601.	1.4	0
176	The Natural History of Myeloma Patients Who Relapse Early After High Dose Therapy.. Blood, 2012, 120, 3125-3125.	1.4	0
177	Impact of Myeloablative Total Body Irradiation Versus Chemotherapy on Late Effects and Survival Among Adolescent and Young Adult Survivors of Hematopoietic Cell Transplantation for Acute Leukemia: A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis. Blood, 2018, 132, 252-252.	1.4	0
178	Absence of Damaging Effects of Stem Cell Donation in Unrelated Donors Assessed By FISH and Gene Variance Screening. Blood, 2019, 134, 4474-4474.	1.4	0
179	Building a National CML Registry. Blood, 2019, 134, 3440-3440.	1.4	0
180	Health-Related Quality of Life in a Biologic Assignment Trial of Reduced Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients Aged 50-75 with Advanced Myelodysplastic Syndrome. Blood, 2021, 138, 421-421.	1.4	0

#	ARTICLE	IF	CITATIONS
181	Cancer and Treatment Distress (CTXD) and Confidence in Survivorship Information (CSI) Trends in Older (≥60 Years) Allogeneic Hematopoietic Cell Transplantation (AlloHCT) Survivors. Blood, 2021, 138, 4123-4123.	1.4	0
182	Impact of COVID-19 Pandemic on Global Unrelated Stem Cell Donations in 2020 - Report from World Marrow Donor Association. Blood, 2021, 138, 3887-3887.	1.4	0
183	Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: Secondary Analysis of Two Randomized Controlled Trials on Survivorship Care Plans. Blood, 2021, 138, 431-431.	1.4	0
184	Impact of Cryopreservation of Donor Grafts on Outcomes of Allogeneic Hematopoietic Cell Transplant (HCT). Blood, 2020, 136, 33-34.	1.4	0
185	Improving Donor Selection for Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide through Selective HLA-Mis/Matching. Blood, 2020, 136, 24-26.	1.4	0
186	236 Optimizing Haploidentical Donor Selection for Pediatric Hematopoietic Cell Transplant. Journal of Clinical and Translational Science, 2022, 6, 37-38.	0.6	0
187	Incorporating patient-reported outcome data into a hematopoietic cell transplant survival calculator.. Journal of Clinical Oncology, 2022, 40, 7045-7045.	1.6	0